Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

   

NOTICE OF ANNUAL GENERAL MEETING IN asarina pharma AB (publ)

The shareholders of Asarina Pharma AB (publ) (the “Company”) are hereby summoned to attend the Annual General Meeting (“AGM”) on 5 May 2020, at 10.00 CEST at Erik Penser Bank, Apelbergsgatan 27 in Stockholm, Sweden. Registration starts at 09.30 CEST and will stop when the meeting starts. NOTE: This is an unofficial translation of the…

Full PDF
   

Asarina Pharma to release historic Phase IIb PMDD data on schedule

Asarina Pharma expects to release top-line results of its Phase IIb PMDD study on schedule at the end of April. Asarina Pharma’s other studies on menstrual migraine and Tourette syndrome also remain on track. The company’s digital R&D Day, on March 26, will detail four key metrics it will use to evaluate the efficacy of…

Full PDF
   

Asarina Pharma R&D Day 2020 to go digital

Asarina Pharma’s March 26 R&D day will now be streamed live via digital link due to Coronavirus restrictions. The event focuses on preparing for the upcoming study results in the company's leading indication PMDD, and will still include presentations from PMDD practitioners, patients and leading researchers. Asarina Pharma will also host a study results presentation…

Full PDF
   

Invitation to Asarina Pharma R&D Day 2020

Asarina Pharma invites institutional investors, financial analysts and media to join its R&D day, focused on the upcoming Study results in the company's lead indication PMDD.

Full PDF
   

Asarina Pharma AB (publ) Year-end 2019 Report released

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today publishes its Q4 and Year-end report for 2019. CEO Peter Nordkild: “We have been very busy during an intensive last quarter of 2019 progressing Sepranolone in all three of our indications; PMDD, menstrual migraine and Tourette syndrome and raising SEK 48 million in a directed share issue.”  

Full PDF
Press release Asarina Pharma Q4 PR ENG d3